Results 91 to 100 of about 45,681 (215)

Responsive nitric oxide‐releasing antibacterial materials for biofilm‐associated infections: Mechanisms, design strategies, and applications

Responsive Materials, EarlyView.
This review summarizes the recent progress in responsive NO‐releasing materials and their applications in biofilm‐associated infectious diseases. The design principles and response mechanisms are given to provide inspiration toward the future development of multi‐responsive NO‐releasing materials.
Wenyue Sun, Meiqi Li, Di Nan, Jiaqi Zhao, Yu Chen, Yao Gao, Shichen Zhang, Kirsten L. Van Landuyt, Manlin Qi   +8 more
wiley   +1 more source

IID572: A New Potentially Best-In-Class β‑Lactamase Inhibitor

, 2019
Resistance in Gram-negative bacteria to β-lactam drugs is mediated primarily by the expression of β-lactamases, and co-dosing of β-lactams with a β-lactamase inhibitor (BLI) is a clinically proven strategy to address resistance. New β-lactamases that are
Shaul, Jacob, Dita Rasper (6518135), Robert L. Simmons (1730614), Anthony Casarez (6518117), Blais, Johanne, Luis Gamboa (6518123), Alun Bermingham (2413702), Growcott, Ellena, Lopez, Sara, Tashiro, Kyuto, Sandro Nocito (4516072), Flavio Ossola (1909075), Rasper, Dita, Louis Metzger (6518129), Shen, Xiaoyu, Jacob Shaul (6518138), Dazhi Tang (6017072), Cindy Li (4715433), Kaci Phizackerley (6518132), Metzger, Louis, Folkert Reck (2694517), Charles R. Dean (308355), Colvin, Richard, Simmons, Robert L, Johanne Blais (3417245), Cazarez, Anthony, Phizackerley, Kaci, Nocito, Sandro, Dean, Charles, Reck, Folkert, Bermingham, Alun, Sara Lopez (2675767), Yue, Qin, Ossola, Flavio, Markus Furegati (1730608), Xiaoyu Shen (4715430), Kyuto Tashiro (6518141), Furegati, Markus, Li, Cindy, Qin Yue (1505008), Richard Colvin (6518120), gamboa, Luis, Tang, Dazhi, Ellena Growcott (6518126)   +43 more
core   +1 more source

Expression of ESBL, MBL and AmpC B lactamases by extra intestinal Escherichia coli isolates: correlation with treatment and clinical outcome

Journal of Microbiology and Infectious Diseases, 2013
Objective: We investigated the expression of Extended Spectrum β-Lactamases (ESBLs), AmpC β lactamases and Carbapenemases in extraintestinal pathogenic Escherichia coli (ExPEC) isolates and correlated with treatment and outcome of the patients.Methods ...
Arindam Chakraborty, Prabha Adhikari, Shalini Shenoy, Shrikala Baliga, Satish Rao, Dhanashree B, Vishwas Saralaya   +6 more
doaj   +1 more source

Reusing health records from farm animal practices at scale: A potential complementary method of surveillance

Veterinary Record, EarlyView.
Abstract Background Disease in primary care frequently represents a surveillance blind spot, particularly for diseases affecting farm animals. Methods Electronic health records (EHRs) were collected from four farm animal veterinary practices in Wales (February 2024‒January 2025) as part of a pilot study.
Beverley Hopkins, Peers Davies, Peter‐John Noble, Anna Bunford‐Davies, April Lawson, Gina Pinchbeck, Ifan Lloyd, Robert Smith, Alan D. Radford   +8 more
wiley   +1 more source

Clinically Significant Infections in Surgical Mortality

ANZ Journal of Surgery, EarlyView.
ABSTRACT Introduction Clinically significant infections (CSIs) are a common complication identified in cases of surgical mortality, associated with prolonged hospital stays, unplanned escalation of care and increased risk of death. This study aimed to examine the burden of CSIs in surgical deaths in the Australian Capital Territory and identify ...
Emily‐Rose Lodge, Helena S. Kopunic, Nathan E. K. Procter, Sivakumar Gananadha   +3 more
wiley   +1 more source

Structure-Based Approach for Binding Site Identification on AmpC β-Lactamase

, 2016
β-Lactamases are the most widespread resistance mechanism to β-lactam antibiotics and are an increasing menace to public health. Several β-lactamase structures have been determined, making this enzyme an attractive target for structure-based drug design.
Rachel A. Powers (1345839), Brian K. Shoichet (434829)   +1 more
core   +1 more source

Effect of a β-lactamase inhibitor, tazobactam, on growth and penicillin-binding proteins ofBorrelia burgdorferi [PDF]

FEMS Microbiology Letters, 1991
Carl Urban, James J. Rahal, Benjamin Luft   +2 more
openaire   +1 more source

Targeting protein–protein interactions with reversible covalent modalities: Non‐cysteine chemistries

British Journal of Pharmacology, EarlyView.
Abstract Protein–protein interactions (PPIs) are central to diverse cellular functions, and represent a rapidly expanding class of therapeutic targets. Advancements in covalent drug design have enabled small‐molecule drugs to overcome challenges associated with engaging these targets, such as limited durations of action and difficult‐to‐drug (expansive,
Ruchira Basu, Steven Fletcher
wiley   +1 more source

A Concise Synthesis of a β-Lactamase Inhibitor

, 2016
MK-7655 (1) is a β-lactamase inhibitor in clinical trials as a combination therapy for the treatment of bacterial infection resistant to β-lactam antibiotics.
Mark A. Huffman (1601572), Nelo Rivera (1601731), Ian K. Mangion (1814908), Rebecca T. Ruck (1436683), Michael Shevlin (1392781)   +4 more
core   +1 more source

Postβ-Lactamase-Inhibiting Effect of Sulbactam in Combination with Ceftriaxone on Extended-Spectrum-β-Lactamase-Producing Escherichia coli

Antibiotics
Background/Objectives: Extended-spectrum β-lactamase (ESBL)-producing Escherichia coli poses a significant global health challenge, as it leads to antimicrobial treatment failure and is associated with elevated mortality rates.
Ru Wang, Kun Mi, Aihua Lu, Chengyang Zhang, Lei Sun, Yuxiang Chen, Yuanhu Pan, Yanfei Tao, Lingli Huang   +8 more
doaj   +1 more source